

## MTN Manual of Operational Procedures (MOP)

### Section 14: Laboratory Issues

<b>14. LABORATORY ISSUES</b> .....	<b>14-2</b>
<b>14.1 Microbicide Trials Network Laboratory Program</b> .....	<b>14-2</b>
14.1.1 Microbicide Trials Network Laboratory Quality Assurance Policy .....	14-2
14.1.2 Microbicide Trials Network Laboratory Quality Control Policy .....	14-2
<b>14.2 MTN Laboratory Quality Assessment and Quality Control Program</b> .....	<b>14-3</b>
<b>14.3 Assessment of Clinical Research Site Laboratory Performance</b> .....	<b>14-3</b>
14.3.1 Non-U.S. Clinical Research Site Laboratories.....	14-3
14.3.2 Non-Affiliated External Laboratories Outside the U.S.....	14-3
14.3.3 Proficiency Testing.....	14-5
<b>14.4 Laboratory Center Oversight of Study-Site Laboratories</b> .....	<b>14-5</b>
<b>14.5 Laboratory Monitoring by the Clinical Safety Monitoring Group</b> .....	<b>14-5</b>
<b>14.6 Specimen Handling and Processing</b> .....	<b>14-6</b>
14.6.1 Primary Lab Specimen Labels and Templates (Macros) Provided by the Statistical and Data Management Center.....	14-6
14.6.2 Laboratory Data Management System.....	14-6
14.6.3 Specimen Shipping.....	14-6
<b>14.7 Policy for Testing of Stored Specimens</b> .....	<b>14-8</b>
<b>14.8 Destruction of Samples</b> .....	<b>14-9</b>
14.8.1 Destruction of Samples Not Consented for Long Term Storage.....	14-10
14.8.2 Large Scale Post Study Closure Specimen Destruction/Release.....	14-11
<b>14.9 Validation of HIV Antibody-Testing Algorithms</b> .....	<b>14-11</b>
<b>14.10 Centralized Testing</b> .....	<b>14-12</b>
<b>14.11 Laboratory Safety</b> .....	<b>14-12</b>
<b>14.12 Document Standards</b> .....	<b>14-12</b>
<b>14.13 Training and Competency</b> .....	<b>14-13</b>
<b>14.14 Method Validation</b> .....	<b>14-13</b>
<b>14.15 Quality Assessment Testing</b> .....	<b>14-13</b>

## 14. LABORATORY ISSUES

All Microbicide Trials Network (MTN) study sites are required to adhere to the requirements of the Division of AIDS (DAIDS) Laboratory Policy, *Requirements for Laboratories Performing Testing for DAIDS-Supported and/or Sponsored Clinical Trials* (<https://www.niaid.nih.gov/sites/default/files/laboratorypolicy1.pdf>) and the current version of the *DAIDS Good Clinical Laboratory Practice* (GCLP) guidelines . Additionally, all local MTN site-specific Standard Operating Procedures (SOPs) for the proper collection, processing, labeling, transportation and storage of laboratory specimens must be followed. In most cases, laboratories with Clinical Laboratory Improvement Amendments (CLIA) certification may submit this certificate as documentation of GCLP compliance.

### 14.1 Microbicide Trials Network Laboratory Program

#### 14.1.1 Microbicide Trials Network Laboratory Quality Assurance Policy

The MTN Laboratory Center (LC) has developed and implemented a general network laboratory quality assurance (QA) policy entitled “*Laboratory Quality Assurance and Quality Assessment Policy*” that is the basis for a range of QA activities carried out by the MTN LC and site laboratories. This laboratory QA policy is designed to monitor, evaluate and improve the quality of laboratory data; ensure the reliability of test data; and evaluate the competency of the site laboratory staff. The Clinical Trials Units (CTUs) and their associated Clinical Research Site(s) (CRS) are responsible for implementing the QA policy at the CTU/CRS laboratories; oversight is done primarily through DAIDS sponsored laboratory audits.

The objectives of the MTN laboratory QA policy (and related programs) are to:

- Ensure that QA activities are comprehensive, coordinated and that appropriate information is reviewed and reported
- Establish, maintain, support and document an ongoing QA program that includes effective and systematic mechanisms for monitoring, collecting, and evaluating information about important aspects of laboratory data to identify opportunities for improving data analysis and participant care
- Assist in improving care and identifying problems through continuous monitoring by focusing on identification, assessment, correction and follow-up of problems that affect data analysis and participant care
- Implement corrective action when problems or opportunities are identified
- Follow up on identified problems to ensure improvement and resolution

The complete QA policy is attached to this Manual as Appendix I. See Appendix II for the QA policy specific to HIV testing.

#### 14.1.2 Microbicide Trials Network Laboratory Quality Control Policy

CTU/CRS laboratory quality control (QC) activities are an integral part of the laboratory QA program. The CTU/CRS QC program is divided into the following main areas of focus:

- Internal QC (testing of known materials)
- Parallel testing (validation of new controls and reagent lots)
- Blinded or split-sample testing

- External Proficiency testing programs
- QC monitoring (corrective action logs)
- QA program feedback
- Preventative maintenance program

Further guidance for developing a site QC program that incorporates these components is contained in Appendix III.

## **14.2 MTN Laboratory Quality Assessment and Quality Control Program**

Each CTU/CRS involved in MTN research is expected to develop a site-specific laboratory QA/QC plan to expand on the generic *Laboratory Quality Assurance and Quality Assessment Policy* (Appendix I) and *Laboratory Quality Control Policy* (Appendix III) instituted by the MTN LC. The site-specific QA/QC plan is designed to ensure accurate, timely and reliable test results by providing routine monitoring of the overall laboratory operation.

## **14.3 Assessment of Clinical Research Site Laboratory Performance**

### **14.3.1 Non-U.S. Clinical Research Site Laboratories**

DAIDS has arranged for non-U.S. local laboratories that participate in MTN research to receive proficiency panels from the College of American Pathologists (CAP), the United Kingdom National External Quality Assessment Service (UK NEQAS) and other approved proficiency providers. The panels are sent to sites based on the assays performed for the specific MTN trials in which the site is participating. The MTN LC requires each site to re-enroll each year based on the assays that are/will be done at that specific site via the DAIDS GCLP Contractor, Immunology Quality Assurance Group (IQA) and Virology Quality Assurance Group (VQA). The MTN LC follows the results and communicates directly with the sites regarding any potential issues or problems with the results and works with the sites to identify corrective actions, as needed. This oversight is achieved as part of a cross-network collaboration with other U.S. National Institute of Allergy and Infectious Diseases (NIAID) HIV/AIDS clinical trials networks, IQA, VQA and the DAIDS GCLP Contractor as part of the Primary Network Laboratory (PNL) system. The DAIDS GCLP Contractor at the time of this writing is the Patient Safety Monitoring in International Laboratories (pSMILE) group and is subject to change.

In addition, laboratories may undergo an assessment by the Clinical Site Monitoring Group (CSMG) and periodic audits by the Clinical Research Support Services (CRSS) DAIDS Lab Audit Contractors. Subsequent reports are submitted through DAIDS, including recommendations for and assistance on addressing existing or potential problems. The MTN LC reports annually on-site performance in the proficiency testing program and shipping quality to the MTN Network Evaluation Committee.

### **14.3.2 Non-Affiliated External Laboratories Outside the U.S.**

Non-affiliated laboratories are laboratories (often commercial) that an MTN site contracts with and pays to perform tests on specimens collected during an MTN study. The MTN site may also use non-affiliated laboratories as part of a back-up plan (see [Guidelines for Use of Back-Up Equipment and Back-up Laboratories for Safety Testing in DAIDS-Sponsored Clinical Trials, Guidelines for the Use of Back-Up Equipment and Back-Up Clinical Laboratories in DAIDS-Sponsored Clinical Trials Networks Outside of the USA](#)). As such, the MTN LC has developed

and implemented strategies to assess and monitor performance of non-affiliated laboratories that receive and process specimens from non-U.S. MTN sites.

#### **14.3.2.1 Requirements for Sites Using Non-Affiliated External Laboratories**

DAIDS has specific requirements for sites that send samples to external non-affiliated laboratories. It is the overall responsibility of the site to ensure that the conduct of testing meets established quality standards including MTN, DAIDS and local standards/requirements. This includes verification of documentation, such as testing SOPs, document control, and staff training. Sites may periodically send external non-affiliated laboratories blinded positive and negative specimens (controls) along with test specimens. This provides a basis for monitoring the performance of external non-affiliated laboratories and assists those laboratories in identifying possible problems with their assay procedures. Site staff should consult the MTN LC Manager and/or their PNL contact about which assays to monitor, which control materials to use and what range of external laboratory results to anticipate and consider acceptable for each assay. When necessary, MTN LC staff will assist in obtaining the required control materials. Results are monitored as part of the proficiency panels submitted to UK NEQAS and CAP, as described above.

The MTN LC staff may visit external non-affiliated laboratories that are (or will be) receiving and processing specimens collected during MTN studies. Early visits, prior to initiation of a specific study, will focus on a laboratory's capability to perform required tests. When MTN LC staff travel to MTN sites, they also visit external laboratories when possible, or for specific issues. Reports from these visits will comply with the *MTN Good Documentation Policy* (see Section 9.2 of this Manual) and minimally include reason for visit, visit activities and any action items. Depending on the nature of the visits, the reports may be shared with MTN study management teams, DAIDS, and/or possibly communicated to other DAIDS Networks using the same laboratory.

It is the site's responsibility to ensure that the conduct of testing meets established quality standards including MTN, DAIDS and local standards/requirements. Under the advisement of the MTN LC, it may be necessary to obtain and verify lab certifications, testing SOPs, QA policies, staff qualifications and training and other aspects of GCLP.

#### **14.3.2.2 Responsibilities of Sites for Quality Assessment of Non-Affiliated External Laboratories**

MTN sites that contract with external laboratories for specimen testing must work with the MTN LC and these external laboratories as much as possible to ensure the integrity of the results and handling of specimens. Each MTN study site that uses an external laboratory must:

- Consult with LC staff to determine which assays conducted at external laboratories will require the inclusion of periodic controls and which materials should be used as controls
- Consult with LC staff to determine the minimal frequency for including control samples in assays conducted at external laboratories
- Document the incorporation of known controls into groups of samples submitted to external laboratories
- Collate results of assays done on these controls and fax information to MTN LC monthly (or more often, if requested)
- Maintain archival records that document results for assays performed on control samples
- Consult LC staff immediately in case of unacceptable results to determine a plan for assessing the external laboratory's performance in greater detail and discuss possible plans for corrective action

### 14.3.3 Proficiency Testing

Each site laboratory must complete proficiency testing specifically applicable to each study's design and laboratory needs. The laboratory must pass one round of proficiency testing prior to study activation; blinded external validation panels can fulfil this requirement. Laboratories are subject to repeat proficiency testing as the study is being conducted. Possible outcomes include:

- Any deficiency, regardless of the scoring, will require corrective action by the site laboratory
- A site laboratory's failure to report to the DAIDS GCLP Contractor that a panel has not been received may be considered unsatisfactory
- If the proficiency provider does not grade the results because they were submitted late, the DAIDS GCLP Contractor will grade the results and document that the panel is considered late
- When a site laboratory receives unsatisfactory results on two panels in a row, or two out of three panels, the LC and the DAIDS GCLP Contractor will provide instructions to the laboratory on what corrective action needs to be taken in addition to reporting the corrective action
- When a site laboratory receives unsatisfactory results on two panels in a row, or two out of three, the laboratory's back-up plan may go into effect, in which case the laboratory cannot perform protocol testing for those analytes. The site laboratory, LC, DAIDS Clinical Laboratory Oversight Team (DCLOT) point of contact and the DAIDS GCLP Contractor will confer to decide on a Corrective Action Plan that may include additional panel testing
- For HIV viral load, HIV DNA and CD4 proficiency panel results, the LC will follow the recommendations of the appropriate governing QA partner — the DAIDS GCLP Contractor, VQA or IQA — and take appropriate action based on these recommendations

### 14.4 Laboratory Center Oversight of Study-Site Laboratories

The LC staff may conduct periodic site visits and/or "for cause" site visits to assess the implementation of laboratory QC procedures, including the proper maintenance of laboratory testing equipment and appropriate use of reagents. The purpose and scope of the visit are discussed with site personnel prior to the visit. In addition, the LC may place a temporary laboratory technician/advisor on-site if the need is indicated. Whether on-site or centrally located, the LC staff work directly with the MTN CTU/CRS staff to address and resolve any QC or QA problems that are identified by the site through proficiency testing, site visits or by the site during study preparation or implementation.

### 14.5 Laboratory Monitoring by the Clinical Safety Monitoring Group

DAIDS CSMG Monitors periodically conduct a complete laboratory audit prior to or during the conduct of an MTN study. The Statistical and Data Management Center (SDMC) provides the CSMG Monitors with site-specific laboratory information to enable them to conduct the expected monitoring of specimen processing and storage of study-specific archived samples.

More information about laboratory monitoring may be found on the following Web sites:

- U.S. Food and Drug Administration (FDA): <http://www.fda.gov>

- College of American Pathologists (CAP): <http://www.cap.org>
- U.K. National External Quality Assessment Service: <http://www.ukneqas.org.uk>
- Oneworld Accuracy (OWA):  
<http://www.oneworldaccuracy.com/HealthMetrx/public/prepareHome.do>
- Laboratory Data Management System (LDMS): <https://www.ldms.org/>
- HIV/AIDS Network Coordination (HANC): <http://www.hanc.info>

## 14.6 Specimen Handling and Processing

Only properly trained personnel may perform specimen collection. It is essential that staff is aware of proper collection techniques, container types, special requirements and proper care for research participants. Specimens must be transported to the laboratory under proper conditions and within predefined time limits. In addition, each laboratory is required to use the LDMS for storing and labeling certain biological samples designated for each study.

### 14.6.1 Primary Lab Specimen Labels and Templates (Macros) Provided by the Statistical and Data Management Center

Depending on the study and site needs, the SDMC may provide sites with primary lab specimen label templates. These include but are not limited to the Participant Identification Number (PTID) and a space to write the date and visit code of the visit at which a specimen was collected. Sites may be required to procure the label stock for the primary specimen labels, which are intended for use only on original specimen “containers” (such as vacutainers and slides). If a site has difficulty obtaining label stock and/or if a customized label size is needed (e.g., for Gram Stain slides), the SDMC may provide sites with label stock as well. The MTN LC and SDMC will consider site-specific primary specimen label needs on a study-by-study basis. If a specimen is to be processed, the LDMS labeling system will be used to generate container labels after specimen information has been entered into the LDMS database for a given specimen.

### 14.6.2 Laboratory Data Management System

The Frontier Science and Technology Research Foundation (FSTRF) and the MTN LC provide training and support to local laboratory staff on the use of the LDMS, however each CTU/CRS laboratory is responsible for ensuring its staff members are trained and competent. The CTU/CRS laboratory is responsible for maintaining its LDMS program, including hardware and software upgrades. The MTN LC develops code sheets for each protocol to ensure that specimens are entered correctly into the system. Additional details are included in the Study-Specific Procedures (SSP) Manual for each study.

The MTN SDMC and LC offer pre-printed labels and specimen-tracking sheets to sites to facilitate the entry of specimens into the LDMS database. For each study, the protocol and SSP Manual will indicate which specimens will be stored locally and which will be shipped to the MTN LC for testing. The SSP Manual also will indicate, with instructions, which specimens must be entered into the LDMS database.

### 14.6.3 Specimen Shipping

Specimens will be transported in accordance with International Air Transport Association (IATA) regulations, U.S. federal laws and regulations, and all laws and regulations that govern specimen transport to and from each country. This applies to transporting specimens, test supplies and reagents on site; to and from the clinic and the laboratory; and from the site to the

LC. Study and laboratory personnel who are involved with packaging and transporting specimens must receive adequate and appropriate training to ensure compliance with all applicable guidelines and regulations. Documentation of training must be filed on site and a copy sent to the LC upon request.

The IATA regulates the safe air transportation of dangerous goods in accordance with its legal requirements. The IATA requires training and certification for individuals who are involved with shipping Class 6.2 infectious substances and diagnostic specimens. The IATA regulations define infectious substances, cultures and stocks, biologic products and diagnostic specimens. The regulations also specify the requirements for handling and shipping each of these substances. Diagnostic specimens and infectious substances are further separated into risk groups based on the organism that is known or suspected to be present within the sample.

Definitions of key terms follow:

Class 1: Explosives

Class 2: Gases

Class 3: Flammable Liquids

Class 4: Flammable Solids

Class 5: Oxidizers/Organic Peroxides

Class 6: Toxic and Infectious Substances

- *Division 6.1: Toxic Substances*
  - Guanidinium (chemical preservative)
- *Division 6.2: Infectious Substances*
  - Category A Infectious Substances—Packing Instruction 620 - An infectious substance which is transported in a form that, when exposure to it occurs, is capable of causing permanent disability, life-threatening or fatal disease in otherwise healthy humans or animals. Indicative examples of substances that meet these criteria are given in Table 3.6.D of the *IATA Dangerous Goods Regulations*. Category A substances that affect humans are assigned to UN2814. This includes viral isolates from cultures of HIV and Hepatitis B.
  - Category B Biological Substances, UN3373—Packing Instruction 650 - An infectious substance which does not meet the criteria for inclusion in Category A. Substances in Category B must be assigned to UN3373. For shipping purposes, these are considered to be Category B biological specimens and must be assigned to UN3373. Patient Specimen (this is the definition for a patient specimen) refers to any human or animal material including, but not limited to, excreta; secretions; blood and its components; tissue and tissue fluids; body parts being transported for research diagnosis, investigational activities or disease treatment or prevention.
  - Exempt Human Specimens— no specific packing instruction – definition- Specimens for which there is minimal likelihood that pathogens are present. These specimens are not regulated provided the specimens are packed in packaging which will prevent leakage and is marked “Exempt human specimen” or “Exempt animal specimen”.

Class 7: Radioactive Material

Class 8: Corrosives

Class 9: Miscellaneous Dangerous Goods:

- Dry Ice, UN(1845)—Packing Instruction 954

Renewal of IATA shipping certification is required every two years with an annual review of the *IATA Dangerous Goods Regulations* to check for any new or changed requirements. The

CTU/CRS laboratory personnel are responsible for obtaining the appropriate training and annual *IATA Dangerous Goods Guidelines*. Each staff member who handles shipments must be trained (internally or externally) and certified. New staff must be trained within 90 days of their start date. Site personnel should review IATA regulations, which are updated annually. All training should be documented and kept on permanent file.

Each site should follow local regulations regarding the transportation of samples by dedicated couriers. MTN study sites within the U.S. must follow the U.S. Department of Transportation requirements, which regulate the transportation of infectious substances within the U.S. (See U.S. Code of Federal Regulations [CFR] 49 CFR, Part 171). Sites outside the U.S. are subject to in-country government regulations for transportation of infectious substances.

Importation of human pathogens to the U.S. from abroad requires an importation permit from the U.S. Centers for Disease Control and Prevention (CDC). The MTN LC maintains a worldwide importation license that covers all materials sent from MTN sites to the MTN LC at Magee-Womens Research Institute in Pittsburgh, PA, U.S. Specimens sent from the sites to other locations within the U.S. are not covered under this importation permit.

Specimen shipping may require Specimen or Material Transfer Agreements (MTA). Sites need to notify the LC during study activation of these requirements, so they can be completed before specimen shipping is required.

More information on specimen shipping and shipping materials is available on the following web sites:

- Code of U.S. Federal Regulations: <http://www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFR>
- U.S. Department of Transportation: <http://www.dot.gov/>
- U.S. Postal Service: <http://www.usps.com>
- Saf-T-Pak: <https://apps.saftpak.com/>
- IATA: <http://www.iata.org/index.htm>
- CDC Biohazard Policy: <http://www.cdc.gov/od/ohs/biosfty/biosfty.htm>

To learn more about risk-group assessments, visit these web sites:

- American Biological Safety Association: <https://my.absa.org/tiki-index.php?page=Riskgroups>
- CDC Select Agent Program: <http://www.cdc.gov/od/sap/>
- U.S. National Institutes of Health (NIH): <https://osp.od.nih.gov/>

## 14.7 Policy for Testing of Stored Specimens

Some specimens that are collected as part of an MTN clinical trial may be stored for future use and testing, including as part of an ancillary study (see Section 21 of this Manual). If not used by the Protocol Team to address study objectives, an *Ancillary Study Application* (<http://www.mtnstopshiv.org/resources>) may be required. Non-MTN investigators must also complete an *MTN Materials Transfer Agreement for Specimens from MTN Clinical Studies* form (<http://www.mtnstopshiv.org/resources>) for the use of stored specimens from MTN studies.



All proposed testing of stored specimens must be reviewed and approved by the relevant MTN Protocol Team, MTN Working Groups, and MTN Steering Committee (SC). Assuming approval is obtained, the investigator proposing to test the specimens is responsible for ensuring that the following steps are followed:

1. All primary study endpoints must be ascertained prior to any testing of stored specimens. In addition to ascertaining primary endpoints, all protocol-specified laboratory testing that involves the stored specimens at issue (including QA/QC testing to be performed by the LC) must be completed prior to any other testing of the specimens.
2. All protocol-specified data analyses must be completed and considered final by the protocol team prior to any testing of stored specimens. Retesting of samples for participant safety and clinical management, QA purposes or ambiguous endpoints may be done at the discretion of the LC or site.

***Note:** There may be circumstances in which it is acceptable for the testing of stored specimens to proceed before approval has been obtained and the conditions in items 1 and 2 have been met. In such cases, the Protocol Chair(s), Protocol Statistician, LC Representative and the SC may approve an exemption to these requirements and allow the testing to proceed. The Protocol Chair(s), Protocol Statistician, LC Representative and the SC must be unanimous in their approval of such exemptions.*

3. Any residual specimens remaining in storage from participants who did not consent to long-term storage and/or possible future research testing of their specimens will be destroyed after all primary endpoints have been ascertained, all protocol-specified laboratory testing involving the stored specimens at issue has been completed and protocol-specified data analyses have been completed and determined to be final by the MTN LC and SDMC.
4. After all primary endpoints have been ascertained, all protocol-specified laboratory testing involving the stored specimens at issue has been completed and protocol-specified data analyses have been completed and considered to be final, investigators wishing to perform further testing of stored specimens will inform the MTN LC prior to performing the proposed testing. Investigators wishing access to specimens in long-term storage will need to fill out an *Ancillary Study Application* and MTA (see Section 21 of this Manual). These are sent to the indicated personnel and will be reviewed by the protocol team, the MTN Working Groups, and the MTN SC (see Section 21 of this Manual, for information regarding access to stored specimens). If approval is granted, the investigators may begin work on their proposal.
5. All data analyses, presentations and publications resulting from the testing of specimens collected and stored for possible future research testing in MTN studies will be prepared and reviewed in accordance with relevant DAIDS and MTN policies (see Section 20 of this Manual).

## **14.8 Destruction of Samples**

The CTU/CRS laboratory is responsible for storing samples collected in any MTN study taking place at the site, although some of these samples may be sent out to other laboratories for other required testing as mandated by the specific protocol. If a site is storing specimens after the completion of a study, a determination is made whether to destroy the specimens in question or continue to store them. In certain situations, specimens must be destroyed (for example, specimens from improperly enrolled participants who have been removed from a study, or specimens that per the protocol should not have been stored). The specific protocol team(s) will

notify the LC if specimens need to be destroyed. The LC will then notify the CTU/CRS laboratory if specimens need to be destroyed, and which samples are to be destroyed, per the study team's directive.

Each site will draft an SOP on sample destruction, which should include a form to use to maintain the chain of custody of the samples throughout the destruction process. Laboratory staff should complete the form with the following information: date and time of destruction, protocol number, notifying authority, the nature of the samples, the laboratory staff member's signature and date, and the Laboratory Director or designee's signature and date. Final sign-off is required from the CRS leader or designee. These records should be kept in the appropriate folder. Specimen inventories should be checked prior to destruction. Any discrepancies should be noted and documented on the form. The LC will provide the laboratory with a date by which the specimens must be destroyed. This notification also may include any special requirements for destruction or documentation. Confirmation of destruction will be sent out as requested by the LC. Specimens will be removed from the specimen storage section of the LDMS. For additional details please reference the DAIDS website at <https://www.niaid.nih.gov/sites/default/files/revlabspecdestructionsop.pdf>

**Note:** *In some cases, it may be necessary to store specimens from participants during the screening process before they enroll in a study. If the participant is deferred from the study during a failed screening attempt, the specimens may be destroyed without MTN's authorization. These specimens may be destroyed in real time or batched at the end of the study. Site laboratories are encouraged to verify deferral against their site's screening and enrollment logs to avoid destroying specimens from enrolled participants in error. Specimens from failed screening attempts cannot be shipped away from the site without written approval from the MTN LC or the protocol team.*

#### **14.8.1 Destruction of Samples Not Consented for Long-Term Storage**

Study participants who decline long-term storage will be referred to as non-consenters. Samples from non-consenters are destroyed once all protocol-defined testing is complete. (Note: protocol-defined testing may take several years). Once protocol-defined testing is complete, as confirmed by the SDMC, the MTN LC will contact the SDMC to request site-specific specimen lists for non-consenters. The lists will generally contain PTIDs and location of samples identified by the LDMS laboratory ID or that they were shipped to a non-LDMS lab.

On a study-by-study basis, the MTN LC may request LDMS global specimen IDs or other information to expedite the destruction process. Any other study-specific requirements will be relayed at this point. The SDMC will then generate the lists and send to the MTN LC.

Before initiating sample destruction, the MTN LC will confirm that all protocol defined testing is complete and receive approval for destruction from the Protocol Chair(s), DAIDS Medical Officer (MO) and the MTN Biomedical Science Working Group (BSWG). The LC will then be responsible to initiate and oversee the destruction process with the respective labs where samples are stored.

The LC will instruct CTU/CRS laboratories to cross reference the SDMC list against their records. Any discrepancies will be referred to the SDMC for investigation. Sites may need additional information, such as LDMS global specimen IDs. The MTN LC will relay these requests to the SDMC. Sites will perform destruction per local SOP and inform the MTN LC when destruction is complete. Sites will be responsible for keeping local documentation of sample destruction, which must be provided to the MTN LC upon request. The MTN LC will notify the SDMC and the protocol team(s) when this sample destruction is completed. The

SDMC will then verify in LDMS that all non-consenter samples have been destroyed. **Note:** there is no mechanism for the SDMC to verify the status of samples at non-LDMS labs. The LC will obtain documentation from non-LDMS labs.

#### **14.8.2 Large Scale Post Study Closure Specimen Destruction/Release**

Once a study and its protocol-defined testing are complete destruction or release of all pending samples may be indicated.

The MTN LC point of contact (POC) or designee will ensure that the following groups/people have given authorization for sample destruction/release:

- Protocol Chair(s)
- DAIDS Medical Officer
- IND holder
- Product developer (if different from IND holder)
- BSWG
- MTN SC
- MTN LC PI

Other parties may be contacted for approval as warranted. If any specific people are no longer available, the decision will be made on consensus of the other people/groups. Once all approvals are obtained, the MTN LC POC or designee will move towards destruction/release of samples.

#### **14.9 Validation of HIV Diagnostic Testing**

MTN-affiliated CRSs that perform HIV testing for MTN protocols must validate each HIV test that is used in the algorithm that they intend to use for any MTN study. In cases of discrepant HIV results, the MTN LC must review the validation testing results and make recommendations. FDA-approved HIV tests are sometimes required, especially for MTN protocols conducted under an *Investigational New Drug Application*. In cases where two HIV rapid tests are used, at least one of the two tests must be FDA-approved, unless a waiver of this requirement has been received from the LC and DAIDS. U.S.-based sites that perform HIV testing under CLIA certification or waiver must follow CLIA guidelines; MTN LC will not review a site's validation unless specifically requested.

Site laboratories should use the same venous specimen type (for example, plasma, serum or whole blood) as the protocol uses. If this is not feasible, the site laboratory may use one type of venous specimen to validate all venous specimen types. The MTN does not allow the use of oral fluids for HIV testing.

The validation process requires testing specimens from a minimum of 20 confirmed HIV-infected individuals and a minimum of 20 confirmed HIV-uninfected individuals using an FDA-approved kit along with the kit(s) planned for use in a study, unless the MTN LC specifies otherwise. For cases in which some validations have already been performed, the MTN LC may require additional validation testing with a smaller sample size. If participants gave informed consent to be tested for HIV, it is not necessary to obtain additional informed consent from individuals whose samples will be used in the validation process. Because this is considered a

QA activity, not a research activity, U.S. regulations do not require a review by the Institutional Review Board/Independent Ethics Committee. International sites need to refer to local or in-country regulations.

If validation testing reveals no more than one false-positive or false-negative result, then the test may be considered validated and the MTN LC may grant approval for use in MTN protocols at the site. If testing reveals more than one false-negative or false-positive sample, the LC will suggest steps to resolve the discrepancy. For confirmatory methods that can also yield indeterminate results, the LC will designate appropriate acceptance criteria relative to the method.

Unless otherwise noted, each site should send a Validation Report to the MTN LC Manager describing the validation process it used and the results. Upon review of this documentation, the LC Manager is to indicate in writing that the test has been approved for use in MTN studies.

Unique circumstances at each site may require clarification or modification of this validation process. Sites are encouraged to contact the MTN LC for further guidance and to provide the MTN LC with the plan for completing this requirement in advance of implementation to ensure that the process is adequate. Any questions should be emailed to the MTN LC:

[MTNNetworkLab@mtnstopshiv.org](mailto:MTNNetworkLab@mtnstopshiv.org).

#### **14.10 Centralized Testing**

The MTN LC will oversee any non-standardized testing for new study concepts and future trials. Testing needs to be standardized across the study sites, including any QA or endpoint confirmation testing, unless the MTN Leadership Group and MTN LC have granted prior approval. Each of the MTN LC Core laboratories, which includes the Pharmacology Core, Protocol Support Core, and Virology and Pharmacodynamics Core, participating in batched testing may be required to submit testing plans (including specific timelines) to the MTN LC Principal Investigator (PI). Additionally, specialty laboratories may be used that will provide unique testing not available within the MTN LC Core laboratories. These specialty laboratories will have contracts set up between them and the MTN with specific scope of work provided to ensure testing is completed per protocol and in a timely manner.

#### **14.11 Laboratory Safety**

The transmission of HIV and other blood-borne pathogens can occur through contact with contaminated needles, blood and blood products. All study personnel must take appropriate blood and secretion precautions when drawing blood and shipping and handling specimens for all MTN studies, as currently recommended by the U.S. CDC's Bloodborne Infectious Diseases: Management & Treatment Guidelines.

<https://www.cdc.gov/niosh/topics/bbp/guidelines.html>.

#### **14.12 Document Standards**

All laboratory results must be traceable to a defined source document that is the first place a result was recorded. These must be archived based on the retention policy relevant to each study. Error correction must be performed per current DAIDS standards. Major events in the

laboratory need to be documented appropriately (Note to File, Corrective Action/Preventative Action, etc. in compliance with *MTN Good Documentation Policy* as per Section 9.2 of this Manual) and communicated immediately to the MTN LC representative and the DAIDS Office of Clinical Site Oversight Program Officer. When appropriate, the MTN LC will notify the DCLOT POC. Certain deviations must be documented as a protocol deviation, as per Section 16.6 of this Manual.

### **14.13 Training and Competency**

All staff records must show education records and work experience appropriate to their job description. All employees, as well as their supervisors, must sign their own job description. All clinical lab staff must have documented training and established competency before they are allowed to report test results back to care providers or study clinics or perform certain other laboratory activities (such as phlebotomy). Competency must be re-assessed after the first six months, 12 months and annually thereafter. For further guidelines, refer to Appendix I of this Manual, *Laboratory Quality Assurance and Quality Assessment Policy*.

### **14.14 Method Validation**

All new methods, instruments or test kits must be validated. Changes to existing tests and methods may also require validation. Refer to Appendix IV of this Manual for the *Method Validation Policy*. Testing completed in specialty laboratories (see section 14.11) may not have method validations in place due to the exploratory nature of the work being provided. However, SOPs should be followed and documented in their applicable Quality Management Plan (QMP).

### **14.15 Quality Assessment Testing**

As a site-specific QA measure to verify the HIV-infection status of study participants, the LC reserves the right to perform relevant protocol-related testing. This testing may occur at any time during a study. Specimens from seroconverters and an equal number of HIV-negative participants will be tested to verify local laboratory test results and, under special circumstances, samples tested at a non-MTN centralized location (such as a local commercial laboratory). Discrepancies may be resolved using test methods with different sensitivities.

For Phase IIb–IV studies, or as decided by the MTN LC and the protocol team, the LC will retest baseline plasma/serum samples for the HIV antibody. Specific protocols may require random QA testing from other visits. The MTN LC will test samples from 50 participants or 10 percent (whichever is greater) of randomly selected, enrolled adult participants at each site. Samples from all participants will be retested if there are less than 50 study participants. Follow up for discrepant results will be study-specific.

In the event of a false-positive or false-negative result that changes the infection status of the participant, additional samples from enrolled participants will be retested, with sample sizes determined by the MTN LC. Baseline and seroconversion plasma/serum samples from all seroconverting adult participants, and an equal number of randomly selected samples from uninfected participants matched by follow-up visit, will be retested by the MTN LC using FDA-licensed tests (for example, HIV antibody, HIV DNA PCR or HIV RNA), if necessary. In the

event of an unexpected result (such as a positive baseline sample or a negative endpoint sample in a seroconverter), the MTN LC may decide to retest additional aliquots or time points.

The SDMC is responsible for:

- Notifying the MTN LC when retesting is due for a protocol
- Generating a list of PTIDs for retesting, with associated dates for specimen collection
- Providing the retest list to the MTN LC in standard format
- Obtaining the retest results from the MTN LC
- Comparing the retest results with the results reported on the case report form
- Notifying the MTN LC of any discrepancies and the need for further testing
- Creating and distributing a report of discrepancies for review by the MTN Endpoint Adjudication Committee (EAC)

The LC is responsible for:

- Working with sites to ship samples to the MTN LC for retesting
- Conducting the retesting
- Providing the SDMC with all retest results from the testing
- Working with the study sites to determine the causes of any discrepancies
- Working with the SDMC to collate necessary material for the MTN EAC

Modification from Version 15.0 to 15.1: Subsection 14.8.2 was modified, per MTN Leadership and DAIDS approval, to remove the three-year minimum, study sample retention period previously required following study completion.